When was MNS founded?

MNS was founded in 2022 and raised its 1st funding round 4 years after it was founded.

Where is MNS located?

MNS is headquartered in Leeds, United Kingdom. It is registered at NEXUS DISCOVERY WAY,UNIVERSITY OF LEEDS,LEEDS,ENGLAND,LS2 3AA.

Who is the current CEO of MNS?

Henry James Dunne of MNS. They have also founded 1 company.

How many employees does MNS have?

As of May 31, 2026, the latest employee count at MNS is 12.

Is MNS a funded company?

MNS is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Mar 03, 2026.

When was the latest funding round of MNS?

MNS's latest funding was a $***** Seed round on Mar 03, 2026, with participation from 4 investors. Its primary sector is Drug Delivery. Globally, the Drug Delivery sector has seen $447M in funding in 2026 to date.

Where does MNS rank among its competitors?

MNS ranks 11th amongst 24 active competitors, of which 9 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Terrestrial, which secured $57.3M in Mar, 2026.

Who are the top competitors of MNS?

MNS's top competitors include Insulet, Micron Biomedical and Enable Injections. Among them, Terrestrial secured the most recent funding round in March, 2026.

MNS - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of microneedle patch technology for medication delivery and vaccinations. The company focuses on creating non-invasive, thermally stable patches for simplified self-administration. It aims to provide solutions that overcome logistical challenges associated with traditional healthcare delivery. The technology is designed to empower individuals and communities by increasing access to medication.

Website: www.microneedlesolutions.com/
Email ID: *****@microneedlesolutions.com
Registered Address: NEXUS DISCOVERY WAY,UNIVERSITY OF LEEDS,LEEDS,ENGLAND,LS2 3AA

Key Metrics

Founded Year

2022

Location

Leeds, United Kingdom

Stage

Seed

Latest Funding Round

Seed, Mar 03, 2026, $*****

Investors

Cambridge Angels & 3 more

Ranked

11^th among 24 active competitors

Employee Count

12 as on May 31, 2026

Similar Companies

Insulet & 23 more

View MNS's full profile

MNS is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MICRONEEDLE SOLUTIONS LTD CIN: 13967922 , United Kingdom, Active	Mar 09, 2022	-	2 (As on Mar 31, 2025)

MNS has raised funding over 1 round. Its latest funding round was a Seed round on Mar 03, 2026 for $*****. 4 investors participated in its latest round. MNS has 4 institutional investors.

Here is the list of recent funding rounds of MNS:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 03, 2026	3488642	Seed	7293317	4894931	8639737	2590387

Access funding benchmarks and valuations. Sign up today!

View details of MNS's funding rounds and investors

The founders of MNS are Ian Bartenev and Henry James Dunne. Henry James Dunne is the CEO of MNS.

Here are the details of MNS's key team members:

Ian Bartenev: Co-Founder & CTO of MNS.
Henry James Dunne: Co-Founder & CEO of MNS.

View details of MNS's Founder profiles and Board Members

MNS's employee count trend

MNS has 12 employees as of May 26. Here is MNS's employee count trend over the years:

Uncover MNS's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MNS include Insulet, Micron Biomedical and Enable Injections. Here is the list of Top 10 competitors of MNS, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Insulet 2000, Boston (United States), Public	Manufacturer of wearable, tubeless insulin delivery systems for diabetes management	$120M	Federated Hermes, Piper Jaffray & 13 others	77/100
2nd	Micron Biomedical 2014, Atlanta (United States), Series A	Developer of microneedle patch technology for vaccines and drugs delivery	$33M	Global Health Investment, J2 Ventures & 10 others	60/100
3rd	Enable Injections 2010, Cincinnati (United States), Series C	Provider of a wearable drug delivery solution	$334M	Sanofi, Magnetar & 13 others	59/100
4th	Zosano Pharma 2006, Fremont (United States), Deadpooled	Developer of transdermal drug delivery systems for a broad range of therapeutic indications	$147M	Nomura, HBM Healthcare Investments & 9 others	39/100
5th	Terrestrial 2011, Woburn (United States), Series C	Developer of a microarray patch platform for therapeutic delivery	$57.3M	RA Capital Management, Engine Ventures & 2 others	39/100
6th	Innovodigm 2018, Kolkata (India), Seed	Developer of vaccine delivery devices	$635K	Indian Angel Network, BIRAC & 1 others	36/100
7th	SkinJect 2015, Pittsburgh (United States), Series A	Developer of microneedle patch to treat skin cancer	$2.5M	Topanga Partners, Velocity Fund Partners	34/100
8th	Array Patch 2019, Dublin (Ireland), Seed	Developer of microneedle patch technology for targeted drug delivery applications	$1.9M	Lakesidecapital, Boole Angel Investment Syndicate ... & 1 others	33/100
9th	Raphas 2006, Seoul (South Korea), Public	Developer of microneedle technology for cosmetics and medical applications	-	NHN Investment, Shinhan Venture Investment ... & 5 others	33/100
10th	OBaris 2024, Schlieren (Switzerland), Acquired	Developer of a needle-free, self-applicable transdermal patch for injectables	-	-	31/100
11th	MNS 2022, Leeds (United Kingdom), Seed	Developer of microneedle patch technology for medication delivery and vaccinations	-	Cambridge Angels, Pioneer Group & 2 others	29/100